Okamoto et al reported that greater expression of IDO was demonstrated both in chemoresistant ovarian cancer patients and chemoresistant ovarian cancer cell lines, suggesting that IDO may participate in chemosensitivity via intracellular pathways [17]. This evidence concerns the gene IDO1 and ovarian cancer.